{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:21:37Z","timestamp":1792783297814,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universidade Federal De S\u00e3o Paulo","id":[{"id":"https:\/\/ror.org\/02k5swt12","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Gastric cancer (GC) remains a major global health burden, with poor survival rates. HER2 is a key biomarker for targeted therapy, but discordance between primary tumors and metastases may impact treatment decisions. This meta-analysis evaluated the prevalence and clinical relevance of HER2 status differences between primary gastric cancers and metastatic lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Embase, and Cochrane was conducted for studies assessing HER2 status in matched primary and metastatic gastric cancer samples. Pooled proportions and 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses by metastatic site were performed. Statistical analyses were conducted using R software, version 4.2.3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This meta-analysis included 3,515 patients across 20 studies. The pooled proportion of HER2-positive expression in primary gastric tumors was 13% (95% CI: 12\u201315%; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200968.7%), while HER2-negative tumors accounted for 74% (95% CI: 72%-76%; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200994.9%). In metastatic sites, the overall pooled proportion of HER2-positive lesions was 18% (95% CI: 16%-20%; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200977.3%), with notable variation across anatomical locations: 38% in lung metastases, 31% in liver metastases, 19% in lymph nodes, and 7% in peritoneum. Conversely, HER2-negative metastases accounted for 82% overall (95% CI: 80%-84%; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200978.2%), with proportions of 93% in peritoneum, 81% lymph nodes, 69% in liver metastases, and 62% in lung.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Significant heterogeneity in HER2 expression between primary and metastatic gastric cancer underscores the need for reassessment of HER2 status in metastatic sites. Relying solely on primary tumor samples may lead to underestimation of HER2 positivity and suboptimal therapeutic decisions. Incorporating site-specific HER2 testing into clinical practice may enhance patient selection for HER2-targeted therapies and improve treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-026-04359-9","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:59:21Z","timestamp":1778594361000},"page":"4738-4748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["HER2 discordance between primary and metastatic gastric cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-8135","authenticated-orcid":false,"given":"Francisco Cezar Aquino","family":"Moraes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1604-6759","authenticated-orcid":false,"given":"Luis Henrique Rios Moreira","family":"Rego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4864-5251","authenticated-orcid":false,"given":"Thiago Gorayeb","family":"Rebelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8707-4823","authenticated-orcid":false,"given":"Gustavo Tadeu Freitas Uch\u00f4a","family":"Matheus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3274-9636","authenticated-orcid":false,"given":"Ana C.","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"4359_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"4359_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"4359_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330. https:\/\/doi.org\/10.3322\/caac.21442.","journal-title":"CA Cancer J Clin"},{"key":"4359_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(20)31288-5.","journal-title":"Lancet"},{"key":"4359_CR5","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","volume":"24","author":"AD Wagner","year":"2006","unstructured":"Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903\u20139. https:\/\/doi.org\/10.1200\/JCO.2005.05.0245.","journal-title":"J Clin Oncol"},{"key":"4359_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/ags3.12708","volume":"7","author":"M Iwatsuki","year":"2023","unstructured":"Iwatsuki M, Matsumoto C, Mimori K, Baba H. The comprehensive review of gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) from diagnosis and treatment. Ann Gastroenterol Surg. 2023;7:725\u201332. https:\/\/doi.org\/10.1002\/ags3.12708.","journal-title":"Ann Gastroenterol Surg"},{"key":"4359_CR7","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"key":"4359_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1080\/1354750X.2024.2422965","volume":"29","author":"FCAde Moraes","year":"2024","unstructured":"Moraes FCAde, Rodrigues Sobreira LE, Cavalcanti Souza ME, Burbano RMR. The role of CLDN18.2 in gastric cancer prognosis: a systematic review and meta-analysis. Biomarkers. 2024;29:528\u201338. https:\/\/doi.org\/10.1080\/1354750X.2024.2422965.","journal-title":"Biomarkers"},{"key":"4359_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-11980-w","volume":"24","author":"FCA de Moraes","year":"2024","unstructured":"de Moraes FCA, Pasqualotto E, Chavez MP, Ferreira ROM, De Castria TB, Burbano RMR. Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials. BMC Cancer. 2024;24:240. https:\/\/doi.org\/10.1186\/s12885-024-11980-w.","journal-title":"BMC Cancer"},{"key":"4359_CR10","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.3748\/wjg.v24.i26.2818","volume":"24","author":"T Matsuoka","year":"2018","unstructured":"Matsuoka T, Yashiro M. Biomarkers of gastric cancer: Current topics and future perspective. World J Gastroenterol. 2018;24:2818\u201332. https:\/\/doi.org\/10.3748\/wjg.v24.i26.2818.","journal-title":"World J Gastroenterol"},{"key":"4359_CR11","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1186\/s12885-019-6035-0","volume":"19","author":"H Kim","year":"2019","unstructured":"Kim H, Son S-M, Woo CG, Lee O-J, Kim DH, Yun HY, et al. Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions. BMC Cancer. 2019;19:834. https:\/\/doi.org\/10.1186\/s12885-019-6035-0.","journal-title":"BMC Cancer"},{"key":"4359_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/dc.23212","volume":"43","author":"DD Wong","year":"2015","unstructured":"Wong DD, de Boer WB, Platten MA, Jo VY, Cibas ES, Kumarasinghe MP. HER2 testing in malignant effusions of metastatic gastric carcinoma: is it feasible? Diagn Cytopathol. 2015;43:80\u20135. https:\/\/doi.org\/10.1002\/dc.23212.","journal-title":"Diagn Cytopathol"},{"key":"4359_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"key":"4359_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-013-0252-z","volume":"17","author":"N Boku","year":"2014","unstructured":"Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17:1\u201312. https:\/\/doi.org\/10.1007\/s10120-013-0252-z.","journal-title":"Gastric Cancer"},{"key":"4359_CR15","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","volume":"26","author":"MM Moasser","year":"2007","unstructured":"Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469\u201387. https:\/\/doi.org\/10.1038\/sj.onc.1210477.","journal-title":"Oncogene"},{"key":"4359_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40265-020-01272-5","volume":"80","author":"J Palle","year":"2020","unstructured":"Palle J, Rochand A, Pernot S, Gallois C, Ta\u00efeb J, Zaanan A. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: current knowledge and future perspectives. Drugs. 2020;80:401\u201315. https:\/\/doi.org\/10.1007\/s40265-020-01272-5.","journal-title":"Drugs"},{"key":"4359_CR17","doi-asserted-by":"publisher","first-page":"24735","DOI":"10.1074\/jbc.C000147200","volume":"275","author":"HY Yang","year":"2000","unstructured":"Yang HY, Zhou BP, Hung MC, Lee MH. Oncogenic signals of HER-2\/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J Biol Chem. 2000;275:24735\u20139. https:\/\/doi.org\/10.1074\/jbc.C000147200.","journal-title":"J Biol Chem"},{"key":"4359_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3892\/ijo.2024.5624","volume":"64","author":"H-H Hu","year":"2024","unstructured":"Hu H-H, Wang S-Q, Zhao H, Chen Z-S, Shi X, Chen X-B. HER2+ advanced gastric cancer: current state and opportunities (Review). Int J Oncol. 2024;64:36. https:\/\/doi.org\/10.3892\/ijo.2024.5624.","journal-title":"Int J Oncol"},{"key":"4359_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.133247","volume":"274","author":"RR Malla","year":"2024","unstructured":"Malla RR, Nellipudi HR, Srilatha M, Nagaraju GP. HER-2 positive gastric cancer: current targeted treatments. Int J Biol Macromol. 2024;274:133247. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.133247.","journal-title":"Int J Biol Macromol"},{"issue":"8","key":"4359_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e18654","volume":"9","author":"D Cao","year":"2023","unstructured":"Cao D, Xu H, Li L, Ju Z, Zhai B. Molecular characteristics of gastric cancer with ERBB2 amplification. Heliyon. 2023;9(8):e18654. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e18654.","journal-title":"Heliyon"},{"issue":"5 Suppl 16","key":"4359_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0093-7754(01)90279-9","volume":"28","author":"R Kumar","year":"2001","unstructured":"Kumar R, Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin Oncol. 2001;28(5 Suppl 16):27\u201332. https:\/\/doi.org\/10.1016\/s0093-7754(01)90279-9.","journal-title":"Semin Oncol"},{"issue":"42","key":"4359_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012854","volume":"97","author":"M Ciesielski","year":"2018","unstructured":"Ciesielski M, Szajewski M, P\u0119ksa R, Lewandowska MA, Zieli\u0144ski J, Walczak J, et al. The relationship between HER2 overexpression and angiogenesis in gastric cancer. Medicine (Baltimore). 2018;97(42):e12854. https:\/\/doi.org\/10.1097\/MD.0000000000012854.","journal-title":"Medicine (Baltimore)"},{"key":"4359_CR23","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1038\/onc.2015.489","volume":"35","author":"S Ingthorsson","year":"2016","unstructured":"Ingthorsson S, Andersen K, Hilmarsdottir B, Maelandsmo GM, Magnusson MK, Gudjonsson T. HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR. Oncogene. 2016;35:4244\u201355. https:\/\/doi.org\/10.1038\/onc.2015.489.","journal-title":"Oncogene"},{"issue":"7","key":"4359_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/genes15070903","volume":"15","author":"X Cheng","year":"2024","unstructured":"Cheng X. A comprehensive review of HER2 in cancer biology and therapeutics. Genes. 2024;15(7):903. https:\/\/doi.org\/10.3390\/genes15070903.","journal-title":"Genes"},{"key":"4359_CR25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Bang Y-J, Feng-Yi F, Xu JM, Lee K-W, Jiao S-C, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18:476\u201384. https:\/\/doi.org\/10.1007\/s10120-014-0402-y.","journal-title":"Gastric Cancer"},{"key":"4359_CR26","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00432-022-04208-6","volume":"149","author":"K Kolbe","year":"2023","unstructured":"Kolbe K, Haffner I, Schierle K, Maier D, Geier B, Luber B, et al. Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study. J Cancer Res Clin Oncol. 2023;149:1319\u201329. https:\/\/doi.org\/10.1007\/s00432-022-04208-6.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"4359_CR27","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/modpathol.2011.198","volume":"25","author":"J R\u00fcschoff","year":"2012","unstructured":"R\u00fcschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637\u201350. https:\/\/doi.org\/10.1038\/modpathol.2011.198.","journal-title":"Mod Pathol"},{"key":"4359_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:167\u201392. https:\/\/doi.org\/10.6004\/jnccn.2022.0008.","journal-title":"J Natl Compr Canc Netw"},{"key":"4359_CR29","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10549-011-1632-x","volume":"129","author":"N Houssami","year":"2011","unstructured":"Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD. HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Res Treat. 2011;129:659\u201374. https:\/\/doi.org\/10.1007\/s10549-011-1632-x.","journal-title":"Breast Cancer Res Treat"},{"key":"4359_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejca.2015.09.018","volume":"53","author":"SR Park","year":"2016","unstructured":"Park SR, Park YS, Ryu M-H, Ryoo B-Y, Woo CG, Jung H-Y, et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: results of GASTric cancer HER2 reassessment study 1 (GASTHER1). Eur J Cancer. 2016;53:42\u201350. https:\/\/doi.org\/10.1016\/j.ejca.2015.09.018.","journal-title":"Eur J Cancer"},{"key":"4359_CR31","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/bjc.2011.121","volume":"104","author":"C Bozzetti","year":"2011","unstructured":"Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer. 2011;104:1372\u20136. https:\/\/doi.org\/10.1038\/bjc.2011.121.","journal-title":"Br J Cancer"},{"issue":"5","key":"4359_CR32","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.humpath.2013.12.010","volume":"45","author":"T Wang","year":"2014","unstructured":"Wang T, Hsieh ET, Henry P, Hanna W, Streutker CJ, Grin A. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status. Hum Pathol. 2014;45(5):970\u20135. https:\/\/doi.org\/10.1016\/j.humpath.2013.12.010.","journal-title":"Hum Pathol"},{"issue":"5","key":"4359_CR33","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/modpathol.2012.205","volume":"26","author":"EY Cho","year":"2013","unstructured":"Cho EY, Park K, Do I, Cho J, Kim J, Lee J, et al. Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. Mod Pathol. 2013;26(5):677\u201384. https:\/\/doi.org\/10.1038\/modpathol.2012.205.","journal-title":"Mod Pathol"},{"key":"4359_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"4359_CR35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603\u20135. https:\/\/doi.org\/10.1007\/s10654-010-9491-z.","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"4359_CR36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc. 2018;16(4):195\u2013203. https:\/\/doi.org\/10.1097\/XEB.0000000000000141.","journal-title":"Int J Evid Based Healthc"},{"key":"4359_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153\u201360. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health"},{"key":"4359_CR38","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"4359_CR39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12253-016-0082-5","volume":"23","author":"M Amato","year":"2017","unstructured":"Amato M, Perrone G, Righi D, Pellegrini C, Rabitti C, Di Matteo F, et al. HER2 status in gastric cancer: comparison between primary and distant metastatic disease. Pathol Oncol Res. 2017;23:55\u201361. https:\/\/doi.org\/10.1007\/s12253-016-0082-5.","journal-title":"Pathol Oncol Res"},{"key":"4359_CR40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10147-013-0542-9","volume":"19","author":"Y Geng","year":"2014","unstructured":"Geng Y, Chen X, Qiu J, Zhou Y, Wang J, Liu L, et al. Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer. Int J Clin Oncol. 2014;19:303\u201311. https:\/\/doi.org\/10.1007\/s10147-013-0542-9.","journal-title":"Int J Clin Oncol"},{"key":"4359_CR41","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.humpath.2011.09.004","volume":"43","author":"M Fassan","year":"2012","unstructured":"Fassan M, Ludwig K, Pizzi M, Castoro C, Guzzardo V, Balistreri M, et al. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. Hum Pathol. 2012;43:1206\u201312. https:\/\/doi.org\/10.1016\/j.humpath.2011.09.004.","journal-title":"Hum Pathol"},{"issue":"6","key":"4359_CR42","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/modpathol.2012.228","volume":"26","author":"N Fusco","year":"2013","unstructured":"Fusco N, Rocco EG, Conte CD, Pellegrini C, Bulfamante G, Nuovo FD, et al. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Mod Pathol. 2013;26(6):816\u201324. https:\/\/doi.org\/10.1038\/modpathol.2012.228.","journal-title":"Mod Pathol"},{"issue":"5","key":"4359_CR43","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/jjco\/hyv020","volume":"45","author":"O Gumusay","year":"2015","unstructured":"Gumusay O, Benekli M, Ekinci O, Baykara M, Ozet A, Coskun U, et al. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites. Jpn J Clin Oncol. 2015;45(5):416\u201321. https:\/\/doi.org\/10.1093\/jjco\/hyv020.","journal-title":"Jpn J Clin Oncol"},{"key":"4359_CR44","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3390\/jcm9040935","volume":"9","author":"F Huemer","year":"2020","unstructured":"Huemer F, Weiss L, Regitnig P, Winder T, Hartmann B, Thaler J, et al. Local and central evaluation of HER2 positivity and clinical outcome in advanced gastric and gastroesophageal cancer\u2014results from the AGMT GASTRIC-5 registry. J Clin Med. 2020;9:935. https:\/\/doi.org\/10.3390\/jcm9040935.","journal-title":"J Clin Med"},{"issue":"4","key":"4359_CR45","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11523-012-0223-z","volume":"7","author":"M Imano","year":"2012","unstructured":"Imano M, Satou T, Itoh T, Yasuda A, Kato H, Shinkai M, et al. Peritoneal metastatic lesions of gastric cancer exhibit low expression of human epidermal growth factor receptor 2. Target Oncol. 2012;7(4):213\u20136. https:\/\/doi.org\/10.1007\/s11523-012-0223-z.","journal-title":"Target Oncol"},{"key":"4359_CR46","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/j.1365-2559.2011.04012.x","volume":"59","author":"MA Kim","year":"2011","unstructured":"Kim MA, Lee H-J, Yang H-K, Bang Y-J, Kim WH. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 2011;59:822\u201331. https:\/\/doi.org\/10.1111\/j.1365-2559.2011.04012.x.","journal-title":"Histopathology"},{"key":"4359_CR47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/1746-1596-8-191","volume":"8","author":"M Kochi","year":"2013","unstructured":"Kochi M, Fujii M, Masuda S, Kanamori N, Mihara Y, Funada T, et al. Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes. Diagn Pathol. 2013;8:191. https:\/\/doi.org\/10.1186\/1746-1596-8-191.","journal-title":"Diagn Pathol"},{"key":"4359_CR48","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1590\/S1676-24442013000500010","volume":"49","author":"JE Jung","year":"2013","unstructured":"Jung JE, Ioshii SO. Immunohistochemical assessment of HER2 expression in gastric cancer in a cohort of 118 Brazilian patients. J Bras Patol Med Lab. 2013;49:361\u20137. https:\/\/doi.org\/10.1590\/S1676-24442013000500010.","journal-title":"J Bras Patol Med Lab"},{"key":"4359_CR49","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.humpath.2008.11.014","volume":"40","author":"AH Marx","year":"2009","unstructured":"Marx AH, Tharun L, Muth J, Dancau A-M, Simon R, Yekebas E, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2009;40:769\u201377. https:\/\/doi.org\/10.1016\/j.humpath.2008.11.014.","journal-title":"Hum Pathol"},{"key":"4359_CR50","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.7150\/jca.19984","volume":"8","author":"M-Z Qiu","year":"2017","unstructured":"Qiu M-Z, Shi S-M, Chen M, Wang J, Wu Q-N, Sheng H, et al. Comparison of HER2 and Lauren classification between biopsy and surgical resection samples, primary and metastatic samples of gastric cancer. J Cancer. 2017;8:3531\u20137. https:\/\/doi.org\/10.7150\/jca.19984.","journal-title":"J Cancer"},{"key":"4359_CR51","doi-asserted-by":"publisher","first-page":"10607","DOI":"10.7314\/APJCP.2014.15.24.10607","volume":"15","author":"F Selcukbiricik","year":"2015","unstructured":"Selcukbiricik F, Erdamar S, Buyukunal E, Serrdengecti S, Demirelli F. Is Her-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy? Asian Pac J Cancer Prev. 2015;15:10607\u201311. https:\/\/doi.org\/10.7314\/APJCP.2014.15.24.10607.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"4359_CR52","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3892\/mco.2014.329","volume":"2","author":"R Shibata","year":"2014","unstructured":"Shibata R, Nimura S, Hashimoto T, Miyake T, Takeno S, Hoshino S, et al. Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and\/or metastatic sites of gastric cancer. Mol Clin Oncol. 2014;2(5):751\u20135. https:\/\/doi.org\/10.3892\/mco.2014.329.","journal-title":"Mol Clin Oncol"},{"key":"4359_CR53","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3748\/wjg.v18.i2.150","volume":"18","author":"D Tsapralis","year":"2012","unstructured":"Tsapralis D, Panayiotides I, Peros G, Liakakos T, Karamitopoulou E. Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. World J Gastroenterol. 2012;18:150\u20135. https:\/\/doi.org\/10.3748\/wjg.v18.i2.150.","journal-title":"World J Gastroenterol"},{"key":"4359_CR54","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/PAT.0000000000000323","volume":"47","author":"DD Wong","year":"2015","unstructured":"Wong DD, Kumarasinghe MP, Platten MA, de Boer WB. Concordance of HER2 expression in paired primary and metastatic sites of gastric and gastro-oesophageal junction cancers. Pathology. 2015;47:641\u20136. https:\/\/doi.org\/10.1097\/PAT.0000000000000323.","journal-title":"Pathology"},{"key":"4359_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-012-0163-4","volume":"16","author":"A Nashimoto","year":"2013","unstructured":"Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16:1\u201327. https:\/\/doi.org\/10.1007\/s10120-012-0163-4.","journal-title":"Gastric Cancer"},{"issue":"14","key":"4359_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411403","volume":"24","author":"A Pous","year":"2023","unstructured":"Pous A, Notario L, Hierro C, Layos L, Bug\u00e9s C. HER2-positive gastric cancer: the role of immunotherapy and novel therapeutic strategies. Int J Mol Sci. 2023;24(14):11403. https:\/\/doi.org\/10.3390\/ijms241411403.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4359_CR57","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.ejca.2012.10.018","volume":"49","author":"HE Lee","year":"2013","unstructured":"Lee HE, Park KU, Yoo SB, Nam SK, Park DJ, Kim H-H, et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer. 2013;49(6):1448\u201357. https:\/\/doi.org\/10.1016\/j.ejca.2012.10.018.","journal-title":"Eur J Cancer"},{"key":"4359_CR58","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.2992089","volume":"229","author":"CR King","year":"1985","unstructured":"King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985;229:974\u20136. https:\/\/doi.org\/10.1126\/science.2992089.","journal-title":"Science"},{"issue":"3","key":"4359_CR59","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.gie.2023.03.030","volume":"98","author":"MA Al-Haddad","year":"2023","unstructured":"Al-Haddad MA, Elhanafi SE, Forbes N, Thosani NC, Draganov PV, Othman MO, et al. American Society for Gastrointestinal Endoscopy guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers: methodology and review of evidence. Gastrointest Endosc. 2023;98(3):285-305.e38. https:\/\/doi.org\/10.1016\/j.gie.2023.03.030.","journal-title":"Gastrointest Endosc"},{"key":"4359_CR60","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s12282-015-0615-x","volume":"23","author":"Y Nakayama","year":"2016","unstructured":"Nakayama Y, Nakagomi H, Omori M, Inoue M, Takahashi K, Maruyama M, et al. Benefits of using the cell block method to determine the discordance of the HR\/HER2 expression in patients with metastatic breast cancer. Breast Cancer. 2016;23:633\u20139. https:\/\/doi.org\/10.1007\/s12282-015-0615-x.","journal-title":"Breast Cancer"},{"issue":"5","key":"4359_CR61","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/dc.21389","volume":"39","author":"A Shabaik","year":"2011","unstructured":"Shabaik A, Lin G, Peterson M, Hasteh F, Tipps A, Datnow B, et al. Reliability of Her2\/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma. Diagn Cytopathol. 2011;39(5):328\u201332. https:\/\/doi.org\/10.1002\/dc.21389.","journal-title":"Diagn Cytopathol"},{"issue":"1","key":"4359_CR62","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/dc.23212","volume":"43","author":"DD Wong","year":"2015","unstructured":"Wong DD, de Boer WB, Platten MA, Jo VY, Cibas ES, Kumarasinghe MP. HER2 testing in malignant effusions of metastatic gastric carcinoma: is it feasible? Diagn Cytopathol. 2015;43(1):80\u20135. https:\/\/doi.org\/10.1002\/dc.23212.","journal-title":"Diagn Cytopathol"},{"key":"4359_CR63","doi-asserted-by":"publisher","first-page":"38372","DOI":"10.18632\/oncotarget.5368","volume":"6","author":"S Ahn","year":"2015","unstructured":"Ahn S, Ahn S, van Vrancken M, Lee M, Ha SY, Lee H, et al. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens. Oncotarget. 2015;6:38372\u201380.","journal-title":"Oncotarget"},{"key":"4359_CR64","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10120-015-0502-3","volume":"19","author":"N Tominaga","year":"2016","unstructured":"Tominaga N, Gotoda T, Hara M, Hale MD, Tsuchiya T, Matsubayashi J, et al. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer. 2016;19:553\u201360. https:\/\/doi.org\/10.1007\/s10120-015-0502-3.","journal-title":"Gastric Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04359-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04359-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04359-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:41:32Z","timestamp":1790160092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04359-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":64,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4359"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04359-9","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"21 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not aplicable.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was required for this systematic review with meta-analysis, as all data were already published in peer-reviewed journals. Furthermore, no patients or animals were involved in the design, conduct, or interpretation of our study.","order":5,"name":"Ethics","label":"Institutional review board","group":{"name":"EthicsHeading","label":"Declarations"}}]}}